Amgen's Q4 2020 earnings call presented several key points that could influence the stock's short-term performance:

1. **Strong Volume Growth and Revenue**: Despite the COVID-19 pandemic, Amgen delivered strong sales and earnings, driven by 15% volume growth of its products. This positive performance is likely to be well-received by investors[1][2][3].

2. **Pipeline Advances**: Significant advancements in the pipeline, particularly with sotorasib and tezepelumab, were highlighted. These breakthroughs, especially the filing for sotorasib and the promising data for tezepelumab, are positive indicators for future growth[1][2][3].

3. **Guidance and Outlook**: The company provided robust 2021 guidance, anticipating continued volume-driven growth despite ongoing COVID-19 impacts. The guidance includes revenue expectations of $25.8-$26.6 billion and non-GAAP EPS of $16-$17 per share, which aligns with or slightly exceeds analyst expectations[1][2].

4. **Commercial and Digital Strategy**: Amgen is shifting towards a more digital commercial model, which has shown efficiency and is expected to persist post-COVID. This adaptability is a positive sign for long-term sustainability and cost management[1].

5. **Challenges and Pressures**: The company acknowledged ongoing price pressures, competition in biosimilars, and the impact of COVID-19 on certain product sales. However, these challenges are largely factored into the guidance and do not seem to significantly undermine the overall positive outlook[1][2].

Given these points, the stock is likely to experience a positive impact in the short term due to the strong financial performance, pipeline advancements, and robust guidance.

**Rating: 1**